Other

Edwards Lifesciences Corporation

Charité – Universitätsmedizin Berlin

Helmholtz-Zentrum Geesthacht Zentrum Fur Material Und Kustenforschung Gmbh

Charité-universit{umlaut Over ( )}Ätsmedizin Berlin

Weist, Benjamin

Thieme, Constantin

Reinke, Petra

Babel, Nina

Schmück, Michael

Volk, Hans-Dieter

Baumann, Gert

Felix, Stephan

Brehme, Stefan

Kern, Florian

Petra Reinke

Hans-Dieter Volk

Florian Kern

Ingolf-Pascal Surel

Nicole Faulhaber

Elham Khatamzas

Andreas Lendlein

Karl Kratz

Thomas Weigel

Reiner Spaethe

Karola Lützow

Frank Klein

Friedrich Jung

Robert Koll

Gert Baumann

H P Schultheiss

Michael Schmuck

Markus Hammer

Bernhard Hiebl

Nina Babel

Gana Bold

Andreas Kurtz

Jutta Müller-Derlich

Stephan Felix

Andy R•mhild

Stefan Brehme

Carsten Tschöpe

Felicitas Escher

Constantin Thieme

Benjamin Weist

Michael Schmück

Andy Römhild

The present invention is related to a B-lymphocyte targeting agent for use in a method for the treatment or diagnosis of cardiac insufficiency. Furthermore, it is related to a composition comprising such B-lymphocyte targeting agent and methods for determining whether a patient suffering from cardiac insufficiency is amenable to the use of the B-lymphocyte targeting agent for its treatment.

B-lymphocyte targeting agents for use in a method for the treatment of a disease

The invention relates to a method for generation of T cell preparations that are specific for at least one target antigen, comprising the steps of expanding lymphoid cells in vitro in the presence of a target antigen or peptide fragments thereof in an expansion step, isolating cells that secrete interferon gamma and culturing, the cells in the presence of interleukin 2 and interleukin 7 and either an inhibitor of the mTOR Complex 1, or in the presence of an inhibitor of IL-2/IL-2R interaction. The invention further relates to preparations obtained by the method of the invention.

Antigen-specific central-memory T cell preparations having high CD4+ fraction

The present invention relates to a method for testing different selected materials and/or surface structures for the culture of cells and/or microorganisms.

Method and kit for testing various selected materials and/or surface structures for culturing cells

The present invention relates to peptides or pretide derivatives of the 65kD lower matrix phosphoprotein of human cytomegalovirus. The peptides disclosed are useful for determining whether subjects have een exposed to human cytomegalovirus. Methods for using these peptides or derivatives thereof to determine the peptide-induced production of interferon-&#x3b3; and/or TNF-&#x3b1; in CD8T cells isolated from subjects are also disclosed.

Peptides for vaccination against human CMV

The invention relates to a method for the antigen-specific stimulation of T-lymphocytes with a synthetic peptide library, by preparing a plurality of peptides, each of said peptides comprising a fragment less than the whole of the total amino acid sequence of the antigen, each of said peptides being a minimum of 9 amino acid residues (AAs) in length, and the amino acid sequence of each peptide overlapping with the amino acid sequence of at least one other of said peptides; combining a plurality of the peptides from a) into a peptide library, said peptide library comprises a plurality of the peptides selected such that their collective overlapping amino acid sequences span the total amino acid sequence of the antigen; and incubating a suspension comprising CD8+ T lymphocytes, CD4+ T lymphocytes or a mixture of CD8+ and CD4+ with said peptide library in a single culture run.

Method for antigen-specific stimulation of T lymphocytes with synthetic peptide libraries

The present invention relates to uses of a B-cell-depleting antibody for the treatment of a polyoma virus infection.

Use of a B-cell-depleting antibody for treatment of polyoma virus infections

The present invention relates to peptides or peptide derivatives of the 65 kD lower matrix phoshpoprotein of human cytomegalovirus. The peptides disclosed are useful for determining whether subjects have been exposed to human cytomegalovirus. Methods for using these peptides or derivatives thereof to determine the peptide-induced production of interferon-&#x3b3; and/or TNF-&#x3b1; in CD8T cells isolated from subjects are also disclosed.

Peptides for vaccinating against human CMV

Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then reinfusing the plasma to the patient. The invention is the use of a specific ligand for human immunoglobulin in the manufacture of a column having the ligand coupled thereto, the column being useful for immunoapheresis treatment of a patient with cardiomyopathy. The specific ligand binds, and thereby removes, human autoantibodies which are harmful to cardiac tissue such as antibodies against &#x3b2;-adrenergic receptors, ADP-ATP carriers, &#x3b1; and &#x3b2; myosin heavy chains, and adenine nucleotide translocators. Immunoapheresis treatment using the column results in improvement of hemodynamic parameters such as mean arterial pressure, mean pulmonary pressure, pumonary capillary wedge pressure, right atrial pressure, cardiac output, cariac index, stroke volume index, and systemic vascular resistance.

treatment of cardiomyopathy by removal of autoantibodies

Growing community of inventors

Berlin, Germany

Petra Reinke